JPH08502253A - 細胞媒介性免疫応答の増強方法 - Google Patents
細胞媒介性免疫応答の増強方法Info
- Publication number
- JPH08502253A JPH08502253A JP6509128A JP50912894A JPH08502253A JP H08502253 A JPH08502253 A JP H08502253A JP 6509128 A JP6509128 A JP 6509128A JP 50912894 A JP50912894 A JP 50912894A JP H08502253 A JPH08502253 A JP H08502253A
- Authority
- JP
- Japan
- Prior art keywords
- mycoplasma
- vaccine composition
- administered
- vaccine
- newborn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000021633 leukocyte mediated immunity Effects 0.000 title claims abstract description 11
- 230000002708 enhancing effect Effects 0.000 title abstract description 8
- 241000204031 Mycoplasma Species 0.000 claims abstract description 33
- 230000004044 response Effects 0.000 claims abstract description 20
- 229960005486 vaccine Drugs 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 18
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims description 13
- 230000024932 T cell mediated immunity Effects 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 241000282887 Suidae Species 0.000 claims description 8
- 230000035935 pregnancy Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 230000013011 mating Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241000282373 Panthera pardus Species 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 32
- 230000002163 immunogen Effects 0.000 abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 235000021277 colostrum Nutrition 0.000 description 14
- 210000003022 colostrum Anatomy 0.000 description 14
- 230000008774 maternal effect Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 8
- 230000009696 proliferative response Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000005210 lymphoid organ Anatomy 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000204003 Mycoplasmatales Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229940088592 immunologic factor Drugs 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 amphigen Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000024664 tolerance induction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000702673 Bovine rotavirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008927 postnatal maturation Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95224892A | 1992-09-28 | 1992-09-28 | |
| US07/952,248 | 1992-09-28 | ||
| PCT/US1993/008900 WO1994007531A1 (en) | 1992-09-28 | 1993-09-21 | Method of enhancing cell mediated immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08502253A true JPH08502253A (ja) | 1996-03-12 |
Family
ID=25492700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6509128A Pending JPH08502253A (ja) | 1992-09-28 | 1993-09-21 | 細胞媒介性免疫応答の増強方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0839050B1 (enExample) |
| JP (1) | JPH08502253A (enExample) |
| AT (1) | ATE273022T1 (enExample) |
| AU (1) | AU687750B2 (enExample) |
| CA (1) | CA2145760A1 (enExample) |
| DE (1) | DE69333588T2 (enExample) |
| DK (1) | DK0839050T3 (enExample) |
| ES (1) | ES2225825T3 (enExample) |
| MX (1) | MX9306016A (enExample) |
| PT (1) | PT839050E (enExample) |
| WO (1) | WO1994007531A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009501730A (ja) * | 2005-07-15 | 2009-01-22 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ローソニアワクチンおよびその使用方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001008636A2 (en) | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| KR20040030785A (ko) * | 2001-07-02 | 2004-04-09 | 화이자 프로덕츠 인크. | 마이코플라즈마 하이오뉴모니애로의 1회 투여량 예방접종 |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| CA2612394C (en) | 2005-06-15 | 2017-02-21 | The Ohio State University Research Foundation | Her-2 peptides |
| US8470336B2 (en) | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
| EP2200643B1 (en) | 2007-09-17 | 2013-09-04 | Boehringer Ingelheim Vetmedica, Inc. | A live lawsonia intracellularis vaccine administered in combination with an antibiotic for use in the treatment of lawsonia intracellularis infections in pigs |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| EP2569007B1 (en) | 2010-05-11 | 2015-10-14 | Intervet International B.V. | Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894332A (en) * | 1985-03-27 | 1990-01-16 | Biogen, Inc. | DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins |
| US4985243A (en) * | 1988-01-20 | 1991-01-15 | Ml Technology Ventures, L.P. | Composition and method for protecting against diseases caused by microorganisms |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| AU657907B2 (en) * | 1990-05-29 | 1995-03-30 | Wyeth Holdings Corporation | Mycoplasma hyopneumoniae vaccine |
| US5565205A (en) * | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
-
1993
- 1993-09-21 DK DK93921698T patent/DK0839050T3/da active
- 1993-09-21 ES ES93921698T patent/ES2225825T3/es not_active Expired - Lifetime
- 1993-09-21 AT AT93921698T patent/ATE273022T1/de active
- 1993-09-21 DE DE69333588T patent/DE69333588T2/de not_active Expired - Lifetime
- 1993-09-21 WO PCT/US1993/008900 patent/WO1994007531A1/en not_active Ceased
- 1993-09-21 PT PT93921698T patent/PT839050E/pt unknown
- 1993-09-21 JP JP6509128A patent/JPH08502253A/ja active Pending
- 1993-09-21 AU AU49312/93A patent/AU687750B2/en not_active Expired
- 1993-09-21 EP EP93921698A patent/EP0839050B1/en not_active Expired - Lifetime
- 1993-09-21 CA CA002145760A patent/CA2145760A1/en not_active Abandoned
- 1993-09-28 MX MX9306016A patent/MX9306016A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009501730A (ja) * | 2005-07-15 | 2009-01-22 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ローソニアワクチンおよびその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69333588T2 (de) | 2005-08-04 |
| EP0839050A4 (enExample) | 1998-05-06 |
| EP0839050A1 (en) | 1998-05-06 |
| AU4931293A (en) | 1994-04-26 |
| MX9306016A (es) | 1995-01-31 |
| ATE273022T1 (de) | 2004-08-15 |
| CA2145760A1 (en) | 1994-04-14 |
| ES2225825T3 (es) | 2005-03-16 |
| DK0839050T3 (da) | 2004-10-25 |
| EP0839050B1 (en) | 2004-08-11 |
| PT839050E (pt) | 2004-11-30 |
| DE69333588D1 (de) | 2004-09-16 |
| WO1994007531A1 (en) | 1994-04-14 |
| AU687750B2 (en) | 1998-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU784557B2 (en) | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen | |
| US20170326226A1 (en) | Composition comprising antigens and a mucosal adjuvant and a method for using | |
| JP2638755B2 (ja) | 細菌突然変異体 | |
| WO2019193078A1 (en) | A vaccine for protection against streptococcus suis | |
| US6113916A (en) | Method of enhancing cell mediated immune responses | |
| EP0839050B1 (en) | Method of enhancing cell mediated immune responses | |
| JPH10265393A (ja) | 豚流行性下痢の予防治療剤 | |
| JP2023113631A (ja) | クロストリジウム類毒素を含むワクチン | |
| Gough et al. | Lactogenic immunity to transmissible gastroenteritis virus induced by a subunit immunogen | |
| WO1996010420A1 (en) | Composition and treatment for hyperimmunization with non heat-killed bacteria | |
| RU2145876C1 (ru) | Способ стимулирования иммунного ответа против паразитических гельминтов животных | |
| US7790178B2 (en) | Trivalent vaccine with maternal anitbody transfer via the milk | |
| Schultz | CERTAlN FACTORS TO CONSIDER WHEN DESIGNING A BOVINE VACCINATION PROGRAM | |
| CA2247117C (en) | Immunogenic complex, iscom, for use in preparing a vaccine for juvenile individuals | |
| Kennedy | Role of Immunization | |
| Snodgrass | Enteric viral vaccines for calves | |
| MXPA06001764A (es) | Composiciones y vacunas que contienen antigeno(s) de cryptosporidium parvum y de otro patogeno. | |
| Kaeberle et al. | Pasteurella Vaccination of Ewes | |
| KR19990079333A (ko) | 돼지 유행성 설사병의 예방 및 치료를 위한 난황항체 이용경구용 면역제제 | |
| Cox et al. | Mucosal immune responses following oral immunisation of pigs with fimbrial antigens of enterotoxigenic E. coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040506 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040803 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060418 |